Expanding Medicare to cover weight loss drugs would cost $35 billion over eight years, according to a new report from the ...

Allowing Medicare to cover popular weight loss drugs such as Wegovy and Zepbound could increase federal spending by billions ...

If Medicare were to start covering popular weight loss drugs such as Wegovy and Zepbound, it could increase federal spending ...

Medicare coverage of the drugs would up federal spending by $35 billion from 2026 to 2034. Meanwhile, CNBC tests Abbott’s ...

Expanding Medicare coverage of costly weight loss drugs could come at a steep cost for the federal government. Allowing Medicare to cover obesity medications would increase federal spending by about ...

One of the biggest changes takes effect in 2025. Part D drug plans must cap out-of-pocket spending on covered drugs at $2,000 ...

Medicare coverage of weight loss drugs, if authorized, is seen increasing federal spending by about $35B from 2026 to 2034.

Popular weight loss drugs are so pricey that many may shell out hundreds or even thousands of dollars on them. Some ...

Medicare covers Wegovy as a treatment to reduce the risk of serious cardiovascular events in people who have overweight or obesity. It does not cover Wegovy for weight loss.

According to the Congressional Budget Office, the average 2034 per-user effect could be $650 in savings and $4,300 in costs ...

Total direct federal costs of covering AOMs would increase from $1.6 billion in 2026 to $7.1 billion in 2034, CBO finds.

Medicare is prohibited by law from covering GLP-1 drugs for weight loss. But many beneficiaries can access the drugs anyway.